This study tests whether adding a drug called N-803 to standard BCG therapy works better than BCG alone for people with a type of bladder cancer that hasn't spread into the muscle. About 369 participants will receive either the combination or BCG alone. The goal is to see if the …
Phase: PHASE1, PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 29, 2026 00:21 UTC